Abstract
Regulatory writing is an integral part of the health-product development process. Most nations have a governmental authority (also called a regulatory agency) responsible for determining whether a drug or biologic is sufficiently safe to allow commercial distribution. The product’s manufacturer must provide written documentation to this regulatory agency (called a submission) making an argument for safety and efficacy of the product. The regulatory agency, if it approves of the data and the claims, will file the submission and grant marketing approval. Regulatory writing is the discipline responsible for development of these regulatory documents.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Federal Food, Drug, and Cosmetic Act, Chapter II — definitions, Sec. 201(g)(1). Available at: http://www.fda.gov/opacom/laws/fdcact/fdcactl.htm (Accessed 18 February 2007).
US Food and Drug Administration, Center for Biologics Evaluation and Research, About CBER, http://www.fda.gov/cber/about.htm (Accessed 18 February 2007).
TITLE 21 Code of Federal Regulations, Food and Drugs, Chapter I — Food and Drug Administration, Department of Health and Human Services (continued), Part 600 Biological Products: General — Subpart A General Provisions, Sec. 600.3 Definitions.
US FDA Device Advice, http://www.fda.gov/cdrh/devadvice/312.html, Updated 6/30/1998 (Accessed 18 February 2007).
US Food and Drug Administration, Device Advice, http://www.fda.gov/cdrh/devadvice. Updated 4/23/03. (Accessed 18 February 2007).
Medical Device Directive — 93/42/EEC, http://www.mdc-ce.de/cert_md1.htm (Accessed 18 February 2007).
Annual Report FY 2005. III. Supporting Information. Review for Medical Devices and In Vitro Diagnostics Approval. (1) Approval Review for Medical Devices. Available at: http://www.pmda.go.jp/pdf/3title_supportinginfo_OnlinePDF.pdf (Accessed 19 February 2007).
TITLE 21 Code of Federal Regulations, Food and Drugs Chapter I Food and Drug Administration, Department of Health and Human Services, Subchapter A — General, Part 3 — Product Jurisdiction, Subpart A Assignment of Agency Component for Review of Premarket Applications, §3.2(e)(l-4) Definitions. http://www.fda.gov/oc/ombudsman/part3&5.htm#combo. (Accessed 27 February 2008).
EMEA Home Page, http://www.emea.eu. (Accessed 3 March 2008).
Globepharm, Links to Worldwide Regulatory Agencies, http://www.globepharm.org (Accessed 3 March 2008).
US Food and Drug Administration, FDA Organization, http://www.fda.gov/opacom/7org.html (Accessed 19 March 2007).
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. About ICH, history and future, Available at: http://www.ich.org/cache/compo/276-254-l.html (Accessed 18 February 2007).
Global Harmonization Task Force, General Information, Summary Statement. Available at: http://www.ghtf.org/information/information.htm (Accessed 18 February 2007).
Guidance for Industry, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, Food and Drug Administration Center for Drug Evaluation and Research (CDER), July 2005, Pharmacology and Toxicology.
ICH Harmonised Tripartite Guideline E6(R1) Guideline for Good Clinical Practice: Consolidated Guidance, ICH June 1996, http://www.ich.org (Accessed 27 February 2007).
European Commission, Detailed guidance for the request for authorisation of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial, ENTR/F2/BL D(2003) CT1 Revision 2. October 2005.
Title 21 — Food and Drugs Chapter I — Food and Drug Administration Department of Health and Human Services Subchapter A — General, Part 50 Protection of Human Subjects, Subpart B Informed Consent of Human Subjects, Section 50.20 General requirements for informed consent. [46 FR 8951, Jan. 27, 1981, as amended at 64 FR 10942, Mar. 8,1999].
Title 21 — Food and Drugs Chapter I — Food And Drug Administration Department of Health and Human Services Subchapter D — Drugs for Human Use Part 314 applications for FDA approval to market a new drug, Subpart B Applications, Section 314.50 Content and Format of an application, 314.50 (d)(5)(v). [50 FR 7493, Feb. 22, 1985].
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Efficacy — M4E(R1), Clinical overview and clinical summary of module 2 module 5: clinical study reports, Current Step 4 version dated 12 September 2002.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Wood, L.F. (2009). Developing a target. In: Wood, L.F., Foote, M. (eds) Targeted Regulatory Writing Techniques: Clinical Documents for Drugs and Biologics. Birkhäuser, Basel. https://doi.org/10.1007/978-3-7643-8362-6_1
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8362-6_1
Published:
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-7643-8361-9
Online ISBN: 978-3-7643-8362-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)